3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Colorectal Neoplasms
9
Stomach Neoplasms
6
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Hepatocellular
4
Solid Tumor
3
Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Extranodal NK-T-Cell
2
Lung Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma, Transitional Cell
2
Advanced Solid Tumors
2
Advanced Solid Tumor
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Muscle Invasive Bladder Cancer
1
Interventions
romidepsin
7
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Vincristine
4
Gemcitabine
4
Doxorubicin
4
Cyclophosphamide
4
Prednisone
3
Lenalidomide
3
Azacitidine
3
10-propargyl-10-deazaaminopterin
3
pembrolizumab
2
ixazomib
2
fludarabine phosphate
2
copanlisib
2
Whole-Body Irradiation
2
Vitamin B 12
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Mycophenolic Acid
2
Folic Acid
2
Etoposide
2
Dexamethasone
2
Cyclosporine
2
Bortezomib
2
venetoclax
1
tislelizumab
1
tazemetostat
1
relatlimab
1
prednisolone phosphate
1
pomalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, T-Cell, Peripheral
×
tislelizumab
×
Clear all
NCT04425070
2026-01-05
TOUCH
Antengene Corporation
Phase 1/2
Terminated
56 enrolled